Uses: Xepi® is a topical prescription medicine approved for the treatment of impetigo, a skin infection caused by the bacteria Staphylococcus aureus or Streptococcus pyogenes, and is approved for adults and children two months of age and older.
When using this product:
Most common side effects were:
Pregnancy Warning: There is no available data on Xepi® use in pregnant women to inform a drug associated risk.
Lactation Warning: There is no available data regarding the presence of the active ingredient (ozenoxacin) in human milk, or the effects of ozenoxacin on the breastfed infant or on milk production.
Pediatric Warning: The safety and effectiveness of Xepi® in the treatment of impetigo have been established in patients 2 months to 17 years of age. The safety profile of Xepi® in patients 2 months and older was similar to that of adults.
The safety and effectiveness of Xepi® have not been established in patients younger than 2 months of age.
Geriatric Warning: Clinical studies of Xepi® did not include sufficient numbers of patients aged 65 and older to find out whether they respond differently from younger patients.
Inactive Ingredients: benzoic acid, octyldodecanol, peglicol 5 oleate, pegoxol 7 stearate, propylene glycol, purified water, stearyl alcohol